Eli Lilly and Company· @EliLillyandCo · X·· 22 天前AI 评分42
AI 导读
在#ESMO26上,我们分享了两项在研联合方案用于晚期KRAS G12C突变非小细胞肺癌患者的一线新数据,支持我们应对该疾病未满足需求的工作。了解更多:https://go.lilly.com/vp0tbg
正文
At #ESMO26, we shared new first-line data from two investigational combination approaches for people living with advanced KRAS G12C-mutant non-small cell lung cancer, supporting our work to address unmet needs in the disease. Read more: https://go.lilly.com/vp0tbg
来源:Eli Lilly and Company · x.com